{
    "nctId": "NCT02337764",
    "officialTitle": "A Multicenter, Open-label, Long-term, Phase 3 Study to Evaluate the Safety and Efficacy of TVP-1012 at 1 mg in Levodopa Treated Parkinson's Disease Patients",
    "inclusionCriteria": "* In the opinion of the investigator or sub-investigator, the participant is capable of understanding and complying with protocol requirements.\n* The participant signs and dates a written, informed consent form and any required privacy authorization prior to the initiation of any study procedures.\n* The participant has a diagnosis of Parkinson's disease according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank.\n* The participant has received a levodopa combination drug for \\>= 1 month at the start of the run-in period and has either of the following.\n\n  * Wearing off phenomenon\n  * Decreased response to levodopa combination drugs\n* The participant has been receiving a levodopa combination drug a stable dose regimen since the start of the run-in period.\n* The participant is an outpatient of either sex aged \\>= 30 and \\< 80 years at the time of consent.\n* A female participant of childbearing potential who is sexually active with a nonsterilized male partner agrees to use routinely adequate contraception from signing of informed consent to 1 month after the last dose of the investigational drug.\n* Must have minimum age of 30 Years\n* Must have maximum age of 79 Years",
    "exclusionCriteria": "* The participant has received any investigational medication within 90 days prior to the start of the run-in period.\n* The participant has received TVP-1012 in the past.\n* The participant is a study site employee, an immediate family member, or in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g., spouse, parent, child, sibling) or may consent under duress.\n* Participant has donated 400 mL or more of his or her blood volume within 90 days prior to the start of the run-in period.\n* The participant has Modified Hoehn \\& Yahr stage 5 (or stage 5 at eather on-time or off-time for the participant with wearing off phenomenon) at the start of the run-in period.\n* The participant has severe dyskinesia.\n* The participant has unstable systemic disease.\n* The participant has a Mini-Mental State Examinations (MMSE) score of \\<= 24 at the start of the run-in period..\n* The participant has known or a history of schizophrenia, major or severe depression, or any other clinically significant psychiatric disease.\n* The participant has a history of hypersensitivity or allergies to TVP-1012 (including any associated excipients) or selegiline.\n* The participant has a history of clinically significant hypertension or other reactions associated with ingestion of tyramine-rich food (e.g., cheese, lever, herring, yeast, horsebean, banana, beer or wine).\n* The participant has a history or concurrent of drug abuse or alcohol dependence.\n* The participant has received neurosurgical intervention for Parkinson's disease (e.g., pallidotomy, thalamotomy, deep brain stimulation).\n* The participant has received transcranial magnetic stimulation within 6 months prior to the start of the run-in period.\n* The participant has received selegiline, pethidine, tramadol, reserpine or methyldopa within 90 days prior to the start of the run-in period.\n* The participant has received single agent of levodopa, any psychoneurotic agent or antiemetic medication of dopamine agonist within 14 days prior to the start of the run-in period. However, the participant has been receiving quetiapine or domperidone with a stable dose regimen for \\>= 14 days prior to the start of the run-in period may be included in the study.\n* The participant is required to take any of the prohibited concomitant medications or treatments.\n* If female, the participant is pregnant or lactating or intending to become pregnant during, or within 1 month after the last administration of study medication in this study; or intending to donate ova during such time period.\n* The participant has clinically significant neurologic, cardiovascular, pulmonary, hepatic (including mild cirrhosis), renal, metabolic, gastrointestinal, urological, endocrine, or hematological disease.\n* The participant has clinically significant or unstable brain or cardiovascular disease, such as:\n\n  * clinically significant arrhythmia or cardiac valvulopathy,\n  * heart failure of NYHA Class II or higher,\n  * concurrent or a history of ischemic cardiac disease within 6 months prior to the start of the run-in period,\n  * concurrent or a history of clinically significant cerebrovascular disease within 6 months prior to the stat of the run-in period,\n  * severe hypertension (systolic blood pressure of 180 mmHg or higher, or diastolic blood pressure of 110 mmHg or higher),\n  * clinically significant orthostatic hypotension (including those with diastolic pressure decrease of 30 mmHg or more following postural change from supine/sitting position to standing position), or\n  * a history of syncope due to hypotension within 2 years prior to the stat of the run-in period.\n* The participant is required surgery or hospitalization for surgery during the study period.\n* Participant has a history of cancer within 5 years prior to the start of the run-in period, except cervix carcinoma in situ which has completely cured.\n* The participant has acquired immunodeficiency syndrome (AIDS) \\[including human immunodeficiency virus (HIV) carrier\\], or hepatitis \\[including viral hepatitis carrier such as hepatitis B surface (HBs) antigen or hepatitis C antibody (HCV) positive\\]. However, the participant who has a negative result for HCV antigen or HCV-RNA can be included in the study.\n* The participant with laboratory data meeting any of the following at the start of the run-in period:\n\n  * Creatinine \\>= 2 x upper limit of normal (ULN)\n  * Total bilirubin \\>= 2 x ULN\n  * ALT or AST \\>= 1.5 x ULN\n  * ALP \\>= 3 x ULN\n* The participant has received any of the prohibited concomitant medications or treatments during the run-in period\n* The participant who, in the opinion of the investigator or sub-investigator, is unsuitable for any other reason."
}